Groowe Groowe BETA / Newsroom
⏱ News is delayed by 15 minutes. Sign in for real-time access. Sign in

Biomarker Collaboration and Licensing Deals Report 2016-2026 - Featuring Quanterix, Caris Life Sciences, Alnylam Pharmaceuticals, Guardant Health, Eurofins Scientific and More

globenewswire.com
QTRX Quanterix is mentioned as a company featured in a report on biomarker collaboration and licensing deals. The article does not provide specific sentiment towards Quanterix's performance or prospects. ALNY Alnylam Pharmaceuticals is listed as a company featured in a report about biomarker collaboration and licensing deals. The article itself does not offer a specific sentiment towards the company. GH Guardant Health is mentioned as one of the companies featured in the biomarker collaboration and licensing deals report. The article does not express a specific sentiment about the company's performance or outlook.

Biomarker Collaboration and Licensing Deals Report 2016-2026 - Featuring Quanterix, Caris Life Sciences, Alnylam Pharmaceuticals, Guardant Health, Eurofins Scientific and More Dublin, July 21, 2026 (GLOBE NEWSWIRE) -- The "Biomarker Collaboration and Licensing Deals 2016-2026" has been added to ResearchAndMarkets.com's offering.

This report provides a comprehensive and structured analysis of 590+ biomarker collaboration and licensing deals, delivering a clear and evidence-based view of how partnerships are designed, negotiated, and executed across the market.

The definitive benchmark for biomarker dealmaking

Biomarker partnering is driven by data, discovery, and precision medicine strategies, with deal structures reflecting the role of biomarkers in target identification, patient stratification, and clinical development.

Establish a clear view of market standards

The report enables a precise understanding of how biomarker deals are structured in practice, allowing you to:

Beyond headline deal data, the report provides access to underlying contract documents, enabling a detailed understanding of how agreements are constructed in practice.

This includes:

This level of transparency is critical to understanding how value, risk, and control are allocated within biomarker partnerships, particularly in early-stage discovery and development contexts.

Designed for real-world BD and strategy use

The report is widely used to:

What's included?

Combining comprehensive deal coverage with contract-level insight, this report provides a trusted, evidence-based reference for how biomarker partnerships are structured, negotiated, and valued.

Companies Featured

For more information about this report visit https://www.researchandmarkets.com/r/nc4wfy

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.